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Alexander S. Geha, Jai H. Lee University Hospitals of Cleveland, Cleveland, Ohio
Primary tissue failure is the most frequent indication for reoperation in pa-
tients with a porcine bioprosthetic valve (BPV). Technical hazards of this oper-
ation include cardiac rupture at the atrio-ventricular junction or posterior left
ventricular wall where a strut may be imbedded, damage to the left circum-
flex coronary artery during removal of the degenerated BPV and insertion of
a new prosthesis, and the potential development of a late paravalvular leak.
We describe a new surgical technique that circumvents these problems. It
consists of 1) excision of only the cusp tissue of the BPV; 2) preservation
of the stent and support of the BPV; 3) suturing a reverted St. Jude aortic
valve with extended cuff to the atrial side of the preserved BPV cuff. Our
laboratory measurements and clinical experience indicate that this allows a
St. Jude valve diameter only 2 mm smaller than that of the BPV This partic-
ular approach was used in 13 patients, age 59 to 84 (mean 73) years, who
had one to four (mean 2.3) previous cardiac operations. There were no hos-
pital deaths. During a mean follow-up of 18 months (2-36). there was one
late death due to cancer. All the remaining patients are doing well without
paravalvular leaks or other complications.
Conclusion: By leaving the BPV stent and cuff intact. the need for extensive
dissection is eliminated, thus shortening and simplifying the procedure and
diminishing its attendant morbidity. The described technique offers a safe
and logical approach to patients requiring replacement of a degenerated BPV
and allows the use of a St. Jude valve of comparable size to the SPV
These results demonstrate that in patients with ESRD, use of MV is as-
sociated with significant risk of hemorrhage or stroke, and BV failure due to
prosthetic dysfunction is unusual. Moreover, overall survival is poor in both
MV and BV patients. Therefore, strong preference should be given to BV
instead of MV prostheses in patients on chronic renal dialysis.
John C. Lucke, Ravi N. Samy, B. Zane Atkins, Scott C. Silvestry, James M. Douglas,
Jr., Steve J. Schwab, Walter G. Wolfe, Donald D. Glower. Duke University, Durham,
NC
Whether biological or mechanical valves should be used in patients on
chronic dialysis therapy remains to be clearly defined. Therefore, a retro-
spective review was performed of all 19 patients from our institution with
end-stage renal disease (ESRD) on chronic peritoneal or hemodialysis un-
dergoing aortic (N = 12) or mitral (N = 51 valve replacement. Two patients
underwent aortic and mitral valve replacement. The 9 biological (BV) and
10 mechanical (MV) valve patients had similar ages (56.5 vs. 56.6 yrs) and
cardiovascular risk factors. BV and MV patients combined had an estimated
Kaplan-Meier survival of 60 ± 12% at 12 months and 42 ± 14% at 60 months
with no significant difference in survival between BV and MV patients. MV
patients had a significantly higher rate of postoperative cerebrovascular ac-
cidents or bleeding complications (10/1 0 vs. 0/9; X2 = 17.0, P < 0.001). MV
patients on hemodialysis required frequent reoperation for hemorrhage or
infection at the access site. Furthermore, there were no subsequent reoper-
ations required for BV failure. Only one BV developed prosthetic dysfunction
lat 156 months).
cardia-pulmonary bypass time was 131 minutes. There was no hospital mor-
tality. One patient died 2.5 months after the procedure. Postoperatively 7
patients had no mitral regurgitation, 3 had 1+ and 2 had 2+ mitral regurgi-
tation. Patients resumed normal sinus rhythm an average of 7 days (2-20)
after surgery. At last follow-up 9 patients were in normal sinus rhythm, one
patient uI,derwent radio frequency ablation for focus of atrial tachycardia and
one patient underwent placement of a permanent pacemaker for sick sinus
syndrome. Mitral valve repair combined with the Maze procedure is a safe
operation with satisfactory results.
1813-31 Results of Valve Replacement with Mechanical
versus Biological Prostheses in Patients on Chronic
Renal Dialysis
1813-41 A New Surgical Approach for Replacement of
Degenerated Mitral Bioprostheses
ICEs; acute myocardial infarction, unstable angina, sudden cardiac death) in
pts with ischemic heart disease (IHD). To address this issue, we performed
percutaneous transluminal coronary angioscopy IPTCAS) in 37 pts (65 ± 8
years, 20 male) with chronic IHD. Angioscopic findings were made by two
blinded observers and were compared with coronary angiography ICAG). Pts
were classified into two groups according to the interpretation of lesions;
group YP (9 pts, 58 ± 9 years) and group white (W, 28 pts, 66 ± 14 years). By
CAG, lesions were interpreted in same manner and categorized as a filling
defect, a hazy lesion or a smooth stenosis. All pts were then followed up for
12 months and their subsequent CEs were carefully checked in our outpa-
tient clinic at least in every two to four weeks. In YP group, CEs were found
in 4/9 pts, whereas in WP group, CEs were found only in 1/28 pts (p < 0.05
vs. YP). However CAG morphology could not get any significant different be-
tween CE and non CE pts. Conclusions: (1) YP had a higher risk to culminate
in CEs within one year. Thus YP might be consisted of vulnerable thinner P
that would be easily ruptured by weak stimuli. 12) To predict CEs in chronic
stable IHD, PTCAS is better than CAG.
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John C. Chambers, Jane Somerville, Donald N. Ross. The Royal Brompton and
National Heart Hospital, London, England
The fate of aortic valve replacement by pulmonary autograft was studied by
follow-up of 131 consecutive hospital survivors from the pioneering centre,
the National Heart Hospital. Preoperatively, study patients were 82% male,
aged 11-52 yrs and showed the full spectrum of aortic valve disease. Opera-
tions were between 1967-1985 and outcome was determined at 1993 (mean
21 yrs follow-up) by retrospective analysis of case notes and outpatient as-
sessment of survivors (including transthoracic echocardiography). Follow-up
was 95% complete - only 6 patients were lost.
53 pts died. Actuarial survival at 10, 20 and 25 years was 86%, 59% and
53% respectively. Amongst young patients after the learning curve survival
was 92%, 80% and 76% respectively. 46 pts required reoperation - 35 on
the "aortic" position (83% for autograft regurgitation) and 31 on the "pul-
monary" position (76% for stenosis). Autograft regurgitation was the main
indication for reoperation in 29 pts: in 22 regurgitation occurred early and
progressed, but in 7 it appeared late. Reoperative findings showed malposi-
tion in early failure and degenerative changes (cusp perforation and stretch-
ingl in late failure. Histological analysis of autografts removed up to 22 yrs
after insertion consistently revealed viable cells and minimal valvar calcifica-
tion. Freedom from death and reoperation was 73%, 45% and 35% at 10,
20 and 25 yrs. Pts were not anticoagulated, only one possibly valve related
thromboembolic event was found. There were only 3 definite episodes of
endocarditis on the autograft. The 72 survivors had average NYHA of 1.2. 58
survivors retained their autograft and 59 their original "pulmonary" position
valve replacement. By echocardiography 46/59 autografts showed normal
haemodynamics. Only 13 autografts showed significant dysfunction, invari-
ably regurgitation. 29 of the surviving "pulmonary" position valves were mal-
functioning, usually stenotic.
Conclusion: Excellent long term results when correctly positioned. Little
or no degeneration of the autograft and only 22% need replacement of "pul-
monary" position homografts over 21 yrs.
Surgery for Valvular Heart Disease
1813-1 1The Pulmonary Autograft for Aortic Valve
Replacement - Results at 26 Years
1813-21 Mitral ValVUloplasty Combined with the Maze
Procedure
Elliot Kaplan, Patrick M. McCarthy, Allan L. Klein, Mina K. Chung, Rita L. Vargo,
Delos M. Cosgrove The Cleveland Clinic Foundation, Cleveland, Ohio
Mitral valve repair is the preferred procedure of choice for mitral regurgi-
tation. Mitral valve disease is frequently associated with atrial fibrillation.
Advantages of mitral valve repair are decreased in the patient with chronic
atrial fibrillation. Mitral valve repair was combined with the Maze procedure
for atrial fibrillation in 12 patients from November 1991 to June 1994. The
average age of the 6 men and 6 women was 56 years (42 - 67 years). All
patients had atrial fibrillation for greater than one year. Pre-operatively 9 pa-
tients had 4+ mitral regurgitation, 2 had 3+ mitral regurgitation, and 1 patient
had mitral stenosis. All patients underwent successful mitral valve repair fol-
lowed by the Maze procedure. Mean cross-clamp time was 78 minutes and
